Tokyo, Jan. 8 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060289) titled 'Verification of the effects of ingesting salmon nasal cartilage components on the skin' on Jan. 8.

Study Type: Interventional

Study Design: Basic Design - Single arm Randomization - Non-randomized Blinding - Open -no one is blinded Control - Uncontrolled

Primary Sponsor: Institute - Kansai Electric Power Medical Research Institute

Condition: Condition - Adult men and women Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - To verify the effectiveness of proteoglycan intake in preventing and improving skin fragility Basic objectives2 - Efficacy

Intervention: Interventions/Control_1 - Participants will take one packet of proteoglycan-containing food (10 mg, Ichimaru Pharcos Co., Ltd.) between meals (between breakfast and lunch, lunch and dinner, or dinner and before bedtime) for 12 weeks. Primary and secondary endpoints will be measured at baseline, 4 weeks, 8 weeks, 12 weeks, and 20 weeks.

Eligibility: Age-lower limit - 20 years-old <= Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - (1) Adult males and females (2) Subjects who can be evaluated at the start of the study and at weeks 4, 8, 12, and 20 Key exclusion criteria - (1) Subjects with skin disorders currently using topical medications (including moisturizers) on the measurement area. (2) Subjects currently using steroids. (3) Subjects with severe liver or renal dysfunction. (4) Subjects with heart failure (NYHA classification II or higher) that limits physical activity. (5) Subjects with severe infections, serious injuries, or arthritis. (6) Subjects with a salmon allergy. (7) Subjects currently or within the past three months have been taking functional foods, health foods, or supplements that claim to improve skin health. (8) Subjects with a history of cosmetic procedures or treatments on the measurement area within the past six months. (9) Subjects deemed inappropriate for this clinical study by the attending physician or principal investigator. Target Size - 20

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2025 Year 12 Month 12 Day Date of IRB - 2025 Year 12 Month 12 Day Anticipated trial start date - 2026 Year 02 Month 02 Day Last follow-up date - 2026 Year 12 Month 31 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068935

Disclaimer: Curated by HT Syndication.